0001062993-22-023351.txt : 20221205
0001062993-22-023351.hdr.sgml : 20221205
20221205180545
ACCESSION NUMBER: 0001062993-22-023351
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221202
FILED AS OF DATE: 20221205
DATE AS OF CHANGE: 20221205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HALPERN JOHN D
CENTRAL INDEX KEY: 0001234950
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11460
FILM NUMBER: 221446110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eterna Therapeutics Inc.
CENTRAL INDEX KEY: 0000748592
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 311103425
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10355 SCIENCE CENTER DRIVE
STREET 2: SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (212) 582-1199
MAIL ADDRESS:
STREET 1: 10355 SCIENCE CENTER DRIVE
STREET 2: SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc.
DATE OF NAME CHANGE: 20210325
FORMER COMPANY:
FORMER CONFORMED NAME: NTN BUZZTIME INC
DATE OF NAME CHANGE: 20051230
FORMER COMPANY:
FORMER CONFORMED NAME: NTN COMMUNICATIONS INC
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2022-12-02
1
0000748592
Eterna Therapeutics Inc.
ERNA
0001234950
HALPERN JOHN D
PO BOX 540
PORTSMOUTH
NH
03802
0
0
1
0
Common Stock
205
D
Common Stock
2022-12-02
4
P
0
335920
3.28
A
450961
I
As trustee of family trust
Warrants (Right to Purchase)
3.28
2022-12-02
4
P
0
671840
0.125
A
2023-06-02
2028-12-02
Common Stock
671840
671840
I
As trustee of family trust
Reflects a 1-for-20 reverse stock split effective October 17, 2022.
Held by John D. Halpern
Each share was purchased as part of a unit consisting of one share and two warrants, for a total purchase price of $3.53 per unit.
The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.
The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.
/s/ John D. Halpern
2022-12-05
/s/ Katherine H. Halpern
2022-12-05